2017年国际大会发言汇总
作者头像
Moonshadow 2018-01-09
原创 287 0

上一篇：The efficacy of LOXO-101,a selective TRKI, in adult and pediatric TRK fusion cancers
下一篇：MET amplification(amp) is a major resistance mechanism to osimertinib-From 2017 ASCO POSTER
相关推荐
暂无
暂无相关推荐
评论 (0)
loading...
    回到顶部